View Older Stories View More Recent Stories

Sep 28, 2022 06:30AM Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
Sep 16, 2022 05:07PM Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 16, 2022 05:07PM Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 14, 2022 06:31AM Ocugen (OCGN) Reports Publication of BBV152 Results
Sep 14, 2022 06:30AM Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology
Sep 14, 2022 06:30AM Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology
Sep 8, 2022 07:30AM Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
Sep 8, 2022 07:30AM Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
Sep 6, 2022 07:30AM Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference
Sep 6, 2022 07:30AM Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference
Sep 1, 2022 07:31AM Ocugen (OCGN) Appoints Robert J. Hopkins as Chief Medical Officer, Arun Upadhyay as Chief Scientific Officer
Sep 1, 2022 07:30AM Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer
Sep 1, 2022 07:30AM Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer
Aug 12, 2022 07:30AM Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Aug 12, 2022 07:30AM Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Aug 5, 2022 07:30AM Ocugen Provides Business Update & Second Quarter 2022 Financial Results
Jul 29, 2022 07:30AM Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results
Jul 29, 2022 07:30AM Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results
Jun 21, 2022 07:12AM Ocugen (OCGN) Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
Jun 21, 2022 07:00AM Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
Jun 14, 2022 07:00AM Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’
Jun 13, 2022 07:01AM Ocugen (OCGN) Issued US Patent for Treating Retinal Degenerative Diseases Using Gene Therapy
Jun 13, 2022 07:00AM Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy
Jun 9, 2022 06:17PM Ocugen, Inc. to Present at BIO International Convention 2022
May 24, 2022 07:11AM Ocugen (OCGN) Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition
May 24, 2022 07:11AM Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition
May 23, 2022 07:34AM Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference
May 23, 2022 06:36AM Ocugen (OCGN) Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN
May 23, 2022 06:36AM Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)
May 6, 2022 06:35AM Ocugen (OCGN) Reports EPS of $0.09, Provides Business Update
May 6, 2022 06:33AM Ocugen Provides Business Update and First Quarter 2022 Financial Results
May 2, 2022 07:37AM Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results
Apr 29, 2022 11:36AM Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
Apr 25, 2022 07:33AM Ocugen (OCGN) Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
Apr 25, 2022 07:33AM Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
Apr 19, 2022 05:32PM Ocugen, Inc. to Present at NobleCon18
Apr 18, 2022 07:11AM Ocugen (OCGN) and Bharat Biotech to Commercialize COVAXIN in Mexico
Apr 18, 2022 07:11AM Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America
Apr 12, 2022 08:31AM Ocugen (OCGN) Announces Clinical Hold on Phase 2/3 Study of COVAXIN
Apr 12, 2022 08:31AM Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)
Apr 4, 2022 09:12AM Pre-Open Stock Movers 04/04: (RCAT) (TWTR) (GGPI) Higher; (DWAC) (OCGN) (SBUX) Lower (more...)
Apr 1, 2022 07:40AM Ocugen (OCGN) Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
Apr 1, 2022 07:37AM Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
Mar 23, 2022 07:44AM Ocugen (OCGN) Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
Mar 23, 2022 07:44AM Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
Feb 15, 2022 07:25AM Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options
Oct 26, 2021 07:01AM UPDATE: Ocugen (OCGN) Climbs Pre-Open Amid Reports Covaxin May Get WHO EUA
View More Recent Stories View Older Stories